Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex 0.035 low-dose drug-coated balloon - Interventional News
Drug Coated Balloon | VuMedi
U.S. Drug-Coated Balloons Market Threatened by Reimbursement Cuts and | mddionline.com
Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease - ScienceDirect
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Drug-Coated Balloons Market - Global Outlook and Forecast 2020-2025
Profitable Strategic Report on Peripheral Drug-Coated Balloon
Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease - ScienceDirect
Philips Shares Three-Year Results for Stellarex .035 Drug-Coated Balloon | DAIC
Drug Coated Balloon | VuMedi
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Recent FDA Approvals for Drug-eluting Balloons - Drug-eluting Balloons
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Stellarex Drug Coated Angioplasty Balloons – Vascupedia
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Peripheral Artery Disease Treatment: Paclitaxel & Sirolimus | VER Journal
FDA adcom to pronounce on paclitaxel-coated devices | Evaluate
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review | Journal of the American College of Cardiology
Drug-coated balloons: Technical and clinical progress - Huiying Ang, Tobias R Koppara, Salvatore Cassese, Jaryl Ng, Michael Joner, Nicolas Foin, 2020
FDA Okays Two Stellarex DCBs for Peripheral Artery Disease
Drug Eluting Balloon Market Size & Share Analysis - Industry Research Report - Growth Trends
